Wedbush Cuts Price Target on GTX Inc. (GTXI), But Still Sees Some Value
Tweet
Share
E-mailGet Alerts GTXI Hot Sheet
Price: $1.20 --0%
Rating Summary:
1 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
1 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Wedbush is reiterating its Outperform rating on shares of GTX Inc. (NASDAQ: GTXI), but is slashing its price target from $13 to $6.
Although the FDA placed a a clinical hold on its Capesaris program, due to
rates of venous thromboembolic events in the Phase II prgram, the firm notes the company continues to enroll its enobosarm (Ostarine) Phase III POWER-1 and POWER-2 trials. The POWER-1 and 2 trials account for roughly $5 of its new $6 price target.
"Given that second-line patients were treated with lower doses, had no VTEs, and showed a drop in PSA and free testosterone, we could see a pathway to Capesaris approval in that patient population," reports an analyst at Wedbush. "We are adjusting our model to account for a potential delay in clinical approval for Capesaris, along with adjusting the addressable patient population to include more 2nd-line patients, while decreasing the 1st-line patient penetration rate."
For FY12, the firm raised its EPS estimate from ($0.68) to ($0.63), while reaffirming its $14 million revenue estimate.
For an analyst ratings summary and ratings history on GTX Inc. click here. For more ratings news on GTX Inc. click here.
Shares of GTX Inc. closed at $5.80 yesterday.
Although the FDA placed a a clinical hold on its Capesaris program, due to
rates of venous thromboembolic events in the Phase II prgram, the firm notes the company continues to enroll its enobosarm (Ostarine) Phase III POWER-1 and POWER-2 trials. The POWER-1 and 2 trials account for roughly $5 of its new $6 price target.
"Given that second-line patients were treated with lower doses, had no VTEs, and showed a drop in PSA and free testosterone, we could see a pathway to Capesaris approval in that patient population," reports an analyst at Wedbush. "We are adjusting our model to account for a potential delay in clinical approval for Capesaris, along with adjusting the addressable patient population to include more 2nd-line patients, while decreasing the 1st-line patient penetration rate."
For FY12, the firm raised its EPS estimate from ($0.68) to ($0.63), while reaffirming its $14 million revenue estimate.
For an analyst ratings summary and ratings history on GTX Inc. click here. For more ratings news on GTX Inc. click here.
Shares of GTX Inc. closed at $5.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- JPMorgan Downgrades Bowman Consulting Group Ltd. (BWMN) to Underweight
- Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
